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The internal domain 3 of the heavy chain of human kininogen, a cysteine proteinase inhibitor, was amplified by a polymerase cham reaction from 
the kinmogen cDNA clone phKG36. The DNA fragment was expressed m Escherichm coli using the ompA expression vector pASK40 and the 
resulting protein was isolated from periplasm, purified by S-carboxymethylpapain affinity- and ion-exchange chromatography. The recombinant 
human kininogen domain 3 is 92% pure, reacts with anti-kinmogen antibodies and is acttvely inhibttory. The expected ammo acid sequence of 
ANSM-[G253-S377] kininogen was confirmed; the inhibitor has a molecular mass of 14.396 Da and an tsoelectric pomt of 6.0 (pH). The determined 
K, values of the complexes with papain and cathepsin L are similar to those measured prevtously with proteolytically hberated kininogen domain 
3, and those of smgle-domain cystatins, like chicken egg white cystatin. However. recombinant kininogen domain 3 is a weak inhibrtor of cathepsin 
B (K, = 63 nM) as it has been found for native L-kininogen (k; = 340 nM). 
Kininogen: Human: Cysteine proteinase inhtbitor; Cystatin; Periplasmic expression: E coli 
1. INTRODUCTION 
The kininogens are well studied multifunctional 
glycoproteins [l-3]. In human plasma two forms are 
present, H-kininogen (high molecular weight or HK) 
and L-kininogen (low molecular weight or LK). From 
both kininogen species kinins can be liberated by lim- 
ited proteolysis by kallikreins [4]. Kininogens are 
known to be involved in the inflammatory process, in- 
cluding activation of the intrinsic clotting cascade. 
More recently it was shown that they may also regulate 
the activity of cysteine proteinases such as cathepsin B, 
H and L, as well as calpain I and II [5-91. 
H-Kininogen and L-kininogen are single-chain 
plasma glycoproteins each composed of an N-terminal 
heavy chain, the kinin segment and a C-terminal light 
chain. The heavy chains and the kinin segments of both 
kininogens have identical amino acid sequences. This 
part of the kininogen structure can be subdivided into 
4 domains, the cystatin-like domains, Dl, D2 and D3, 
and the kinin segment, D4. The light chains of both 
kininogens differ remarkably; they can be subdivided 
into domain D5 (LK) and D5, D6 (HK), respectively 
[3,10-121. 
In vitro different cleavage products of kininogens 
were liberated by limited proteolysis and analysed 
[ 12.131. Salvesen et al. [ 121 showed that domains D2 and 
D3 are potent inhibitors of papain and cathepsin L, 
domain D2 is also an inhibitor of chicken calpain, 
whereas domain Dl is not actively inhibitory against 
any of the proteinases tested so far. Recent studies of 
Schmaier and co-workers with fragments produced by 
proteolytic cleavage in vitro indicate that domain D3 
contains a cell binding region for platelets, and. in addi- 
tion, another region which inhibits thrombin binding 
and thus activation of platelets [14]. 
Detailed structural and functional studies with single 
domains of the kininogens are limited by the quantity, 
purity and structural homogeneity of the available start- 
ing material. Hence, defined recombinant kininogen do- 
mains would offer an interesting alternative as com- 
pared to fragments liberated from natural kininogens, 
which are frequently truncated, or to synthetic peptide 
fragments of the domains. Furthermore, variants of re- 
combinant domains can be used to analyze structure- 
function relationships. 
Here we report the design, cloning, expression, purifi- 
cation and biochemical characterization of a recombi- 
nant unglycosylated kininogen domain 3 (rKD3). 
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2. MATERIALS AND METHODS 
2.1. Matrrrals and generul methods 
Chemical reagents and materials for molecular biology, protem 
Abbrevrations: rKD3, recombmant human kimnogen domain 3 chemistry and biochemistry studies were purchased from Merck, 
(ANSM-[G253-S377] kininogen); PCR, polymerase chain reactton; Sigma, Boehringer. New England, Biolabs, Applied Biosystems, 
IPTG, isopropyl-j?-o-thiogalactoside. Bachem. Oligonucleotide prtmers were synthestzed in the laboratory 
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of Prof. H. Wolf, Max von Pettenkofer Institut, Miinchen, the cDNA 
clone phKG36 was kindly supplied by S. Nakanishi, Kyoto. The 
polymerase chain reactions (PCRs) were accomplished usmg equtp- 
ment from Perkin-Elmer. The standard techniques of molecular clon- 
ing were performed as described elsewhere [15] 
2.2. PCR and nmlecular cloning 
The EcoRI-hneartzed cDNA clone, pHKG36 [IO], was used as a 
template for PCR with the primers al: GGGAATTCCA 
TGGGGAAGGA TTTTGTACAA CCACCTACC containing an 
EcaRI and a NcoI site, and bl: GAGGATCCGT CGACTTACTA 
TGAGATCATT CCCAGTGGTT GACA contammg a Bm7HI. a 
SalI site and two stop codons. The PCR was carried out accordmg to 
a standard procedure [16]. The fragments were precipitated with etha- 
nol, digested with f&RI and UI. purified on a low meltmg-point 
agarose gel (2% NuSieve. SeaKem) and isolated using the kit of Gen- 
clean (Genclean; Bio 101). About 60 fmol of the expression unit were 
ligated with 6 fmol of the appropriately prepared pASK40 DNA [ 171. 
Competent E coli JM 83 cells (arad(lac-proAB),rpsL,phi80, 
lacUM15) were transformed. Transformants were selected after re- 
striction analysis and DNA sequencing (Pharmacia, T7 sequencing 
kit) of plasmid DNA. Expression was analysed after SDS/PAGE of 
total E co11 proteins. 
2 3. E.~pres.non. Jrrmentution md isolation 
The selected E co17 stram 1263 (harbourmg the vector pDR 13.1 1) 
was grown at 33°C m 2 x YT media (200 pg ampicillm/ml), induced 
with I mM IPTG at OD,,, of approx. 0.8 for about 557 h either m 
shaker flasks or in a BioStat E fermenter with an ES-IO culture vessel 
(Braun-Diessel Btotech) at 2O”C, 550 rpm, pH 7.4. aeration 5 standard 
Vmin and foam control. Cells were harvested by centrifugation 
(Sorvall RC3B, 5000 rpm, 15 mm at 8°C) and the recombinant protein 
was isolated from pertplasma [18]. Cells were resuspended at 0°C for 
4 mm in 20% w/v sucrose. 0.2 M Tris-HCl. pH 8.0. 0.1 M EDTA, 
centrifuged at 6,000 x g and the supernatant was filtrated through a 
Filtron mmisette omega 0.16 pm membrane. The recombinant mate- 
rial of this periplasmic fraction was purified by S-carbouymethyl- 
papain affinity chromatography [I 81 followed by ion-exchange chrom- 
atography on Fractogel EMD-TMAE 650s. Merck. loaded with 25 
mM bisTris-HCI. pH 6.0 and eluted with a pH gradient from 6 0 to 
4.8 [20] on a BioPilot system from Pharmacia. 
2.4. Protein dlarwtrrlsatior7 
The amount of protein was quantified by ilzra determination using 
A 280 1% = 1 ng/nl and by the Bradford assay from Bto-Rad 
SDS-PAGE was performed on lo-20% polyacrylamide gels accord- 
ing to Laemmh [21] and gels were stained with Coomasste blue or 
silver Polyclonal and monoclonal antibodies (anti-kmmogen IgG. AS 
165 and HKH 11. kmdly provided by W. Muller-Esterl, Mamz) were 
used for immuno printing after Western blot analysts [Xl. Purified 
proteins (2-3 nmol) and tryptic digests of them were resolved by 
HPLC on a reverse-phase column (100 RP-18. 5 pm Licrochart. 
Merck) as described for AEF [SI M M291 M89L] chicken cystatm 
[19]. Ammo acid sequence analyis was done with a gas-phase se- 
quencer 473 A (Applied Biosytems) followmg the mstructtons of the 
manufacturer. 
The papam inhibitory activity of the material was determmed ac- 
cordmg to Barrett and Knschke [23]. Kinetic constants for the interac- 
tion of rKD3 and human L-kinmogen (Medor) with papam. actindin, 
human cathepsin B and human cathepsm L. were determined using 
materials and methods as described [19.24.25]. 
3. RESULTS AND DISCUSSION 
3.1. Design und cloning of rKD3 
In order to produce a biosynthetically stable and 
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Fig. 1. SDS-PAGE and corresponding immunoblot analysis (mono- 
clonal antibody HKHl 1 directed against domain3 of HK) of E coli 
proteins and isolation products. Lanes: M. low molecular mass 
marker (indicated in kDa); A. lysate of 6 h Induced E coli (2 x IO8 
cells); B, periplasmtc fraction of 6 h Induced E. coil (3 pug): C, eluate 
from CM-papain Sepharose 4B (2pg) with ANSM [G253-83773 kinm- 
ogen domam 3 (upper band) and truncated forms (lower bands), D. 
main fractions after anion-exchange chromatography (2 pg) 
functionally active protein domain from a cDNA of a 
multifunctional protein the appropriate segment has to 
be carefully selected. For the construction of a cDNA 
expression unit of the human kininogen domain D3 we 
considered the results available on limited proteolysis of 
kininogens [ 12,131. sequence alignment of cystatins [26], 
the exon-intron junctions of kininogen genes [l 11, and 
our experience in synthesis and expression of recombi- 
nant cystatin variants. Using primers al and bl, to- 
gether with the cDNA phKG36. a DNA fragment was 
produced by PCR. The material was purified and li- 
gated into pASK 40, a periplasmatic E. coli expression 
vector. The expected DNA sequence coding for ANSM 
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Fig. 2 Elution profile of rKD3 from Fractogel EMD-TMAE amon- 
exchange chromatography. dotted lines. pH gradient (main fractions 
from number 38 to 18). 
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Fig. 3. Amino acid sequence of ANSM [G253-S377] kminogen. The 
sequenced N-terminal part and the sequenced regions of tryptic pep- 
tides (T) are underlined. Numbering with asteriks (*) is accordmg to 
the amino actd sequence m pHKG36 cDNA clone. 
[G253-S377] kininogen was confirmed. The resulting 
vector was named pDR 13.1 .l. and used for transfor- 
mation of E. coli JM 83. 
3.2. Expression and isolation 
The host strain, E. coli 1263 (JM 83xpDR13.1.1.) 
expressed 24 mg rKD3 per 1, which is equivalent to 
l-2% of total E. coli protein as judged by SDS-PAGE 
(Fig. 1). Using a standard procedure for isolation of 
periplasmic proteins [17], the actively inhibitory mate- 
rial was found mainly in the buffer solution containing 
sucrose/EDTA before osmotic-shock treatment. The 
material was enriched by a factor of approx. 10 after 
this step (Fig. 1); contamination by other proteins is 
very low. 
Recombinant chicken egg white cystatin, a molecule 
quite similar to rKD3, was expressed in a 2-fold higher 
yield [ 191 and could be obtained mainly in the superna- 
tant after the osmotic-shock treatment. The kininogen 
domain D2, which is very similar to rKD3, was also 
constructed and cloned in parallel, but could not be 
expressed using the approaches for rKD3 and other 
cystatins [20]. At present we do not know the reason for 
this different expression and secretion behaviour of 
quite similar and functionally related molecules in E. 
coli. 
3.3. PuriJication and protein analysis 
The periplasmatic material was bound to a carbox- 
ymethyl-papain affinity column, developed with a pH 
shift from 6.5 to 11, and the eluant neutralized. The 
material thus obtained was about 80% pure. The major 
protein band migrated at the expected position of 15 
kDa and showed a specific papain inhibitory activity of 
1040%. It was contaminated with minor additional 
protein fractions which were identified by reverse-phase 
HPLC analysis and isoelectric focussing (2 major and 
34 minor bands with isoelectric points between 5.2 and 
6.0 (data not shown)). N-Terminal amino acid sequence 
analysis revealed four distinct sequences: the expected 
sequence rKD3 (about 80%) as well as three minor 
sequences CVGC (12%) MGK (4%) and FVQ (3%), 
which represent N-terminally truncated forms of rKD3. 
Using Fractactiveogel TMAE anion-exchange 
chromatography we could separate some of the trun- 
cated proteins (Fig. 2). The main fraction (Fig. 2) mi- 
grated as a single band in SDS-PAGE (Fig. l), eluted 
as a sharp peak after HPLC and showed a single isoelec- 
tric point of 6.0 (data not shown). However, by N- 
terminal sequencing we found, as well as the correct 
rKD3 sequence (91%) three minor N-terminally short- 
ened forms which could not be separated by ion-ex- 
change chromatography. The results of a typical purifi- 
cation of rKD3 from E. coli are given in Table I. After 
immuno printing and Western blotting minor heteroge- 
neous rKD3 expression products could be detected in 
E. coli lysates (data not shown). This may be explained 
by an inaccurate endoproteolytic cleavage by the signal 
peptidase which, however, has not been described for 
Table I 
Results of a typical purification of ANSM[G253-S377] kininogen from E. coli 
Purification step 
E. coli cell lysate 
Periplasmic fractton 
Cm-papain Sepharose 4B 
Fractogel TMAE main fractions 
Volume Total protein Active maternal Specific activity 
(ml) (mg) (mg) (%) 
1,000 300 n.d n.d. 
200 12 1.2 10 
7 2 0.8 40 
5 0.7 0.3 42 
Yteld 
(%) 
100 
66 
25 
Total protein was esttmated wtth the Bradford assay (bovine serum albumin as standard); active material was calculated from papain mhtbitory 
assays: yield is given as percentage of isolated active material; n.d. = not determined. 
95 
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Table II 
Inhibition constants (K,) and rate constants (li,, and k,,) for the inhibition of cysteine protemases by recombinant human kminogen domain 3 
Inhibitor 
ANSM-rKD3 
L-Kminogen 
cew cystatin 
Cathepsm L Papam Actimdm Cathepsin B 
k,,, (Mm’ s-‘) k,, (s-’ ) K,, WI) k,, (M-’ s-‘) k,, (s-‘) 4, WQ K, (nM) K, @M) 
10.5 x 10’ 1.0x lOA 0.0010 3.0 x 10’ 5.4 x 1om5 0.0018 6 63.4 
30x 10’ 1.1 x lomJ 0.0035 2.0 x 10’ 6.4 x lo-’ 0.0032 23 340 
11.0 x lo7 3.5 x lo-’ 0.0003 14x IO’ 2.0 x lo-’ 0.0014 18 2.9 
The corresponding data obtained with L-kminogen (determmed m the same set of experiments) and natural chicken egg white cystatin (cew cystatm, 
from [24] are included for comparison. K, of the complexes with cathepsin L and papain were calculated from the rate constants as K,, = k,, lk,,; 
K, for the interaction with actidmm and cathepsin B were determined in equilibrium inhibition experiments. 
ompA up to now but has been shown for pho A expres- 
sion systems or by other proteolytic enzymes present in 
the periplasm [27]. 
To confirm the primary structure of recombinant 
ANSM [G253-S377] kininogen, 13 out of 17 theoreti- 
cally expected tryptic peptides were isolated and identi- 
fied by partial sequencing. The first 36 amino acid resi- 
dues of the intact protein were also shown by sequence 
analysis to be identical with the expected sequence. The 
internal peptides T8, TlO, Tll, and the C-terminal T13 
peptide, were sequenced completely (Fig. 3). As ex- 
pected, the recombinant E. coli protein is not glycosyl- 
ated. 
3.4. Characterization of inhibitory activity? 
Inhibitory activity measured by the papain inhibition 
assay was detected during all steps of the isolation pro- 
cedure. The purified material contained about 40% ac- 
tively inhibitory material if referred to protein concen- 
tration (Table I). 
The complex dissociation constants (K,) given in 
Table II show that rKD3 is a tight-binding inhibitor of 
papain and cathepsin L but a weak inhibitor of actinidin 
and cathepsin B. The inhibitory profile of rKD3 resem- 
bles that of chicken egg white cystatin with the excep- 
tion of the 20-fold lower inhibition of cathepsin B by the 
kininogen domain. The inhibitory effect of rKD3 on 
papain and cathepsin L is comparable to that of prote- 
olytic fragments of natural L-kininogen comprising do- 
main 3 which have been described earlier [12,13]. Previ- 
ously reported [13] higher K, values (S-10 pM for the 
papain-domain 3 complex) may be explained by the fact 
that equilibrium had not been achieved in those experi- 
ments. The weak inhibition of cathepsin B (K, = 340 
nM) is a characteristic feature of L-kininogen [28]. Until 
now no quantitative data had been available on the 
inhibition of cathepsin B by individual kininogen do- 
mains. Our results with rKD3 indicate that domain 3 
itself has a low affinity for cathepsin B (K, = 63 nM). 
The K, of 340 nM for the inhibition of cathepsin B by 
native L-kininogen (based on the actively inhibitory 
concentration obtained by titration with papain) sug- 
96 
gests that the affinity of domain 2 for cathepsin B could 
be even lower than that of domain 3 and might be 
negligible in the presence of domain 3 under equilibrium 
conditions. However, as the binding stoichiometry of 
cathepsin B to human L-kininogen is not precisely 
known, the observed low affinity of complete L-kinino- 
gen for cathepsin B may also be due to mutual steric 
hindrance of two enzyme molecules on binding to the 
two adjacent domain. 
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